

Junzo Kigawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5366258/publications.pdf>

Version: 2024-02-01

26
papers

1,306
citations

858243

12
h-index

759306

22
g-index

27
all docs

27
docs citations

27
times ranked

1716
citing authors

#	ARTICLE	IF	CITATIONS
1	Rethinking the significance of surgery for uterine cervical cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, 48, 576-586.	0.6	3
2	Phase II study of a new multidisciplinary therapy using once every 3 weeks carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 207-215.	1.0	6
3	Impact of Histopathological Risk Factors on the Treatment of Stage IB-IIB Uterine Cervical Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 252, 339-351.	0.5	7
4	Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival. <i>Journal of Clinical Medicine</i> , 2019, 8, 156.	1.0	12
5	Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 99-106.	1.2	63
6	Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e23.	1.0	18
7	Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. <i>Medical Oncology</i> , 2017, 34, 134.	1.2	16
8	Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1128-1135.	1.0	22
9	Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 561-567.	1.2	9
10	Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy. <i>International Journal of Clinical Oncology</i> , 2015, 20, 556-560.	1.0	41
11	The PI3K/mTOR dual inhibitor NVP-BE2235 reduces the growth of ovarian clear cell carcinoma. <i>Oncology Reports</i> , 2014, 32, 553-558.	1.2	35
12	Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy. <i>International Journal of Clinical Oncology</i> , 2014, 19, 348-353.	1.0	17
13	Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: Final results of a multicenter phase II study (Sankai Gynecology Study Group 013).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5526-5526.	0.8	0
14	Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance. <i>Molecular and Clinical Oncology</i> , 2013, 1, 780-784.	0.4	52
15	Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5528-5528.	0.8	0
16	Evaluation of UGT1A1 genotyping for predicting individual toxicity of irinotecan plus platinum analog regimens: Interim safety analysis of a prospective observational study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11049-11049.	0.8	0
17	Chemoresistance in gastric-type mucinous adenocarcinoma of the uterine cervix: Multi-institutional study by Sankai Gynecology Study Group (SGSG).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5526-5526.	0.8	1
18	New strategy for overcoming resistance to chemotherapy of ovarian cancer. <i>Yonago Acta Medica</i> , 2013, 56, 43-50.	0.3	46

#	ARTICLE	IF	CITATIONS
19	Molecular-targeted therapies for ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2012, 17, 423-423.	1.0	2
20	Neoadjuvant chemotherapy of docetaxel and carboplatin in patients with stage Ib2 to IIb nonsquamous cervix cancer of the uterus.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5103-5103.	0.8	1
21	A Case of Pelvic Arteriovenous Fistula. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 2010, 12, 465-468.	0.0	2
22	Ovarian metastasis in carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2006, 101, 234-237.	0.6	188
23	Clinical characteristics of clear cell carcinoma of the ovary. <i>Cancer</i> , 2000, 88, 2584-2589.	2.0	710
24	Clinical characteristics of clear cell carcinoma of the ovary. , 2000, 88, 2584.		1
25	Clinical characteristics of clear cell carcinoma of the ovary. <i>Cancer</i> , 2000, 88, 2584-2589.	2.0	51
26	Sinusoidal Fetal Heart Rate Pattern in Twin Pregnancies. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1986, 12, 347-352.	0.0	1